ISRCTN07139948已完成未知
A randomised double blinded placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis (IPF)
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •A pragmatic clinical definition of IPF will be used, in which recruited patients must fulfill all of the following criteria:
- •1. IPF is considered the most likely diagnosis by the regional interstitial lung disease multidisciplinary team meeting
- •2. History of cough, with or without exertional dyspnoea
- •3. High resolution computed tomography (HRCT) scan features of honeycombing in a predominantly basal and subpleural distribution
- •4. Bibasal crackles on auscultation
- •5. Features of a restrictive ventilatory defect (vital capacity (VC) <90% predicted and/or diffusion factor for carbon monoxide (Tco) <90% predicted)
- •6. Aged 40-85 years
- •Patients with radiological emphysema will be eligible so long as the diagnosis of IPF is secure, i.e., all the features above are satisfied.
- •If the regional ILD-MDT cannot reach a clear consensus as to the diagnosis, the case will be referred to two experts in ILD from outside the region, and the patient will be eligible if both consider IPF to be the most likely diagnosis.
- •Patients taking a PPI during screening will potentially be eligible. In these cases the indication for ongoing treatment will be reviewed.
- •1. Patients taking short courses (e.g., 2 months) of PPI will be eligible once the treatment has been discontinued for a minimum of 1 month.
- •2. There are few licensed indications for long-term omeprazole other than Zollinger-Ellison syndrome. Therefore,
- •unless there is a known diagnosis of Zollinger-Ellison or a history of significant dyspepsia or gastrointestinal bleeding
- •during a previous discontinuation of PPI, patients on long-term PPI will be asked to consider a trial of supervised
- •discontinuation. If he/she agrees and provides written consent to a trial of discontinuation, the GP will be contacted. If
- •both the patient and the GP agree to a trial of discontinuation, the patient will be eligible for the study if he/she provides written consent after at least 2 weeks without PPI.
- •3. Patients taking antacids, prokinetics or raft alginates at the time of screening will be eligible if they have been off these treatments for a period of at least 2 weeks.
- •4. Target Gender: Male & Female; Upper Age Limit 85 years ; Lower Age Limit 40 years
排除标准
- •1. Known allergy to omeprazole or other PPI
- •2. Concomitant use of warfarin, diazepam, phenytoin or ketoconazole
- •3. Concomitant use of a regular PPI, antacid, prokinetic or raft alginate during the trial period.
- •4. History of upper respiratory tract infection, lower respiratory tract infection or exacerbation of IPF in the 4 weeks before starting study drugs
- •5. Active trial of treatment for IPF (e.g., prednisolone, pirfenidone, N-acetylcysteine) started in the 4 weeks before starting study drugs
- •6. Documented history of hepatic cirrhosis
- •7. Pregnancy or lactation
- •8. ILD-MDT considers the most likely cause of the patient?s ILD to be a condition other than IPF, for example rheumatoid lung, systemic sclerosis ILD, asbestosis, chronic hypersensitivity pneumonitis, sarcoidosis, etc.
- •9. Concurrent enrolment in a trial of a Clinical Trials of Investigational Medicinal Product (CTIMP) for IPF
研究者
相似试验
终止
不适用
Pilot study: Can a dairy based protein (IDP) enhance immune responses after influenza vaccination?Immune response to Influenza vaccineInfection - Other infectious diseasesInflammatory and Immune System - Normal development and function of the immune systemACTRN12622000462785Quantec Ltd53
已完成
3 期
Comparison of post-operative mobility recovery in participants undergoing keyhole colorectal surgery treated with intraperitoneal ropivacaine/placebo for post-op pain management.ACTRN12616000359437Hunter New England Local Health District96
招募中
2 期
Homeopathic treatment of heavy menstrual bleedingCTRI/2021/12/038645D N De Homoeopathic Medical College Hospital
进行中（未招募）
1 期
Passion flower and stressSince only healthy volunteers will be included in this study, there is no medical condition to be examined. The indication for PASCOFLAIR® is nervous restlessness, a subclinical state of stress-sensitivity.EUCTR2011-006129-17-DEPASCOE Pharmazeutische Präparate GmbH60
进行中（未招募）
不适用
Investigating the potential health benefits of ergothioneine supplementation for people with metabolic syndromeISRCTN25890011niversity of Leeds108